Shots:

• The P-III CHRONOS-3 study involves assessing Aliqopa (IV) + rituximab vs PBO + rituximab in 458 patients with relapsed iNHL in extending PFS who have received at least one or more lines of prior rituximab-containing treatment
• Results: @median follow-up of 19.2mos.- mPFS (21.5 vs 13.8 mos.)- ORR (80.8% vs 47.7%)- CR (33.9% and 14.6%)- no new safety signals were identified- overall improvement in the prognosis of iNHL patients
• Aliqopa is a PI3K inhibitor with inhibitory activity against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. The data is presented at AACR 2021 and simultaneously published in The Lancet Oncology

  Ref: Businesswire | Image: Business Standard